or
Bookmark and Share
Use of a celecoxib composition for fast pain relief
   
Document Number
US Patent 6579895
Issued Date
June 17, 2003
Link
Inventors
Gao; Ping (Portage, MI)
Map
Abstract
There is provided a method of rapidly relieving pain in a mammalian, preferably human, subject. The method comprises orally administering to the subject an effective pain-relieving amount of a composition comprising celecoxib formulated in such a way as to provide, when tested in fasting humans in accordance with standard pharmacokinetic practice, a blood plasma concentration profile of celecoxib in which a concentration of about 250 ng/ml is attained not later than about 30 minutes after oral administration.
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
29
Comments:
no comments yet
Owner
Pharmacia Corporation (St. Louis, MO)
Published
June 17, 2003
Application Number
09/866,165
Filed
May 25, 2001
US Classification
514/406   514/263.32 514/282 514/317 977/775 977/915 977/926
Int'l Classification
A61K   9/00   (20060101)   A61K   9/14   (20060101)   A61K   31/415   (20060101)  
Examiner
Attorney/Law Firm
Parent Case
CROSS REFERENCE TO RELATED APPLICATION This application claims priority to U.S. application Ser. No. 60/207,729 filed May 26, 2000.
USPTO Field of Search
514/406  
Related Patents
7071220 - N-substituted benzothiophenesulfonamide derivatives - Owned by Toa Eiyo Ltd. (Tokyo,JP)

The present invention relates to an N-substituted benzothiophenesulfonamide derivative or a pharmaceutically acceptable salt thereof and applications thereof. Furthermore, it provides an agent for preventing or treating cardiac or circulatory disease and so on caused by abnormal increase of production of angiotensin II or endothelin I based on chymase activity, or by activation of mast cell, and an agent for preventing adhesion after surgery, wherein the agent has a selective inhibitory action on chymase.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us